摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methyl-octahydro-2-pyrindin | 15367-38-1

中文名称
——
中文别名
——
英文名称
2-Methyl-octahydro-2-pyrindin
英文别名
2-methyl-octahydro-[2]pyrindine;2-Methyl-1,3,4,4a,5,6,7,7a-octahydrocyclopenta[c]pyridine
2-Methyl-octahydro-2-pyrindin化学式
CAS
15367-38-1
化学式
C9H17N
mdl
——
分子量
139.241
InChiKey
YXMLAIMCNQXPSH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    179.9±8.0 °C(Predicted)
  • 密度:
    0.917±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    3.2
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • HEPATITIS B ANTIVIRAL AGENTS
    申请人:ENANTA PHARMACEUTICALS, INC.
    公开号:US20160289212A1
    公开(公告)日:2016-10-06
    The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    本发明公开了化合物的结构式(I),或其药学上可接受的盐、酯或前药: X-A-Y-Z-L-R 1 (I) 这些化合物抑制由乙型肝炎病毒(HBV)编码的蛋白质或干扰乙型肝炎病毒的生命周期功能,并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物,用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
  • N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
    申请人:AbbVie Deutschland GmbH & Co. KG
    公开号:US20130131132A1
    公开(公告)日:2013-05-23
    The present invention relates to N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives of the formula (I), (II), (III) or (IV) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, and the use of such N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives for therapeutic purposes. The N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives are GlyT1 inhibitors.
    本发明涉及式(I)、(II)、(III)或(IV)所示的N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物 或其生理耐受盐。 该发明涉及包含上述N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物的药物组合物,以及将上述N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物用于治疗用途。所述N-取代氨基苯并环庚烯、氨基四氢异喹啉、氨基吲哚和苯基烷基胺衍生物是甘氨酸转运体1抑制剂。
  • BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS
    申请人:GIOVANNINI Riccardo
    公开号:US20120329773A1
    公开(公告)日:2012-12-27
    This invention relates to bicyclic ring system substituted amide functionalized phenols of general formula 1, their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    这项发明涉及通式1的双环环系统取代酰胺功能化酚,其用作CXCR2活性抑制剂,含有相同化合物的药物组合物,以及将其用作治疗和/或预防呼吸道或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症的药剂的方法,以及含有这些化合物的药物组合物。
  • BICYCLIC RING SYSTEM SUBSTITUTED SULFONAMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS
    申请人:GIOVANNINI Riccardo
    公开号:US20120316159A1
    公开(公告)日:2012-12-13
    This invention relates to bicyclic ring system substituted sulfonamide functionalized phenols of general formula 1, their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    这项发明涉及一般式1的双环环系统取代磺酰胺功能化酚,其作为CXCR2活性抑制剂的用途,含有这些化合物的药物组合物,以及将其用作治疗和/或预防呼吸道或消化道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症的药剂的方法,以及含有这些化合物的药物组合物。
  • [EN] PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PURINE EN TANT QU'INHIBITEURS DE CD73 POUR LE TRAITEMENT DU CANCER
    申请人:VITAE PHARMACEUTICALS INC
    公开号:WO2015164573A1
    公开(公告)日:2015-10-29
    Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.
    提供的是新颖化合物、其药学上可接受的盐以及其药物组合物,这些化合物是CD73的抑制剂,并可用于癌症治疗。
查看更多